Plant Based API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Alkaloids, Anthocyanins, Flavonoids, Phenolic Acids, Terpenoids, Lignans and Stilbenes, Others), By Application (Pharmaceuticals, Nutraceuticals, Herbal Based Industries, Others), By Region and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationPlant Based API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Alkaloids, Anthocyanins, Flavonoids, Phenolic Acids, Terpenoids, Lignans and Stilbenes, Others), By Application (Pharmaceuticals, Nutraceuticals, Herbal Based Industries, Others), By Region and Competition
Global Plant Based API Market is expected to grow at an impressive rate during the forecast period on account of the
Plant-based APIs are derived from natural sources, such as herbs, spices, and other plants, and are used to produce a wide range of pharmaceuticals, including antibiotics, painkillers, and anticancer drugs. The growing demand for eco friendly products and need to achieve sustainability goals among countries and governments worldwide will create lucrative opportunities for the growth of global plant based API market in the next few years.
Another driver of the global plant-based API market is the growing interest in plant-based medicines. Traditional medicine has long relied on the healing properties of plants, and many of these natural remedies have been shown to be effective in treating a wide range of ailments. As a result, there is growing interest in the development of plant-based medicines, and plant-based APIs are a key component of this trend.
Growing Interest in Plant Based Medicines
For instance, in 2018, the U.S. Food and Drug Administration (FDA) approved Epidiolex, a drug made from cannabidiol (CBD), a compound found in the cannabis plant.
The increasing interest in plant based pharmaceuticals along with growing demand for plant based products will certainly increase the demand for plant based active pharmaceutical ingredients as well, thereby supporting the growth of global plant based API market.
Increasing Prevalence of Chronic Diseases
For instance, Paclitaxel is a chemotherapy drug used to treat various cancers, including breast, ovarian, and lung cancer. In 2020, a plant-based version of paclitaxel was launched in India.
Advances in Biotechnology and Genomics
Download Free Sample Report
Market Segmentation
Global Plant Based API Market can be segmented by type, by application, and by region. Based on type, the Global Plant Based API market can be categorized into alkaloids, anthocyanins, flavonoids, phenolic acids, terpenoids, lignans and stilbenes, and others. By application, the Global Plant Based API market can be fragmented into pharmaceuticals, nutraceuticals, herbal based industries, and others. Regionally, the Global Plant Based API market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
Market Players
Roquette Frères SA, EVONIK Industries, AG, Cargill, Inc., Kothari Phytochemicals & Industries Ltd, Medipure Pharmaceuticals Inc., Centroflora Group, Arboris, LLCs, BASF SE, Novartis AG, Sanofi SA, GlaxoSmithKline, plc, F. Hoffmann-La Roche AG, among others are some of the leading players operating in the Global Plant Based API market.
Recent Developments
- In 2019, a team of researchersfrom the University of Wisconsin-Madison developed a new platform for producingplant-based APIs using genetically modified tobacco plants. The researcherswere able to produce an anti-inflammatory protein called Interleukin-37 (IL-37)in tobacco plants and demonstrated that the protein was able to alleviatesymptoms of inflammatory bowel disease in mice.
- In2019, Sanofi SA announced a USD 640 million (€600 million) investment in itsFrench production sites, with a focus on plant-based APIs for the treatment ofrare diseases. The investment will support the development of new plant-basedtechnologies, including the use of algae and other microorganisms to produceAPIs. Sanofi has also invested in the production of plant-based insulin, whichwas approved by the FDA in 2020.
- Novartishas also made significant investments in plant-based APIs in recent years, witha focus on the use of plant cell culture technology. In 2020, Novartisannounced a collaboration with Canadian biotech company PlantForm Corporationto develop plant-based biosimilars for the treatment of rare diseases. Novartishas also invested in the development of plant-based vaccines, including acollaboration with Boston-based biotech company VBI Vaccines to develop aplant-based vaccine for COVID-19.
- In2020, Amyris, a California-based biotechnology company, announced that it hadsuccessfully produced a plant-based version of the anti-malarial drugartemisinin. The company used a proprietary yeast strain to produce the drug,which was then licensed to pharmaceutical companies for further development andcommercialization.
- In2021, researchers from the University of Bristol developed a method forproducing a key component of the malaria drug artemisinin using geneticallymodified yeast. This approach offers a more sustainable and cost-effectivealternative to traditional methods of producing the drug, which involveextracting it from the artemisia plant.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | By Type By Application By Region |
| Regional scope | North America, Europe, Asia Pacific, South America, Middle East & Africa |
| Key companies profiled | Roquette Frères SA, EVONIK Industries, AG, Cargill, Inc., Kothari Phytochemicals & Industries Ltd, Medipure Pharmaceuticals Inc., Centroflora Group, Arboris, LLCs, BASF SE, Novartis AG, Sanofi SA, GlaxoSmithKline, plc, F. Hoffmann-La Roche AG |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy